Achilles Therapeutics Plc Stock Buy Hold or Sell Recommendation
| ACHL Stock | USD 1.06 0.01 0.93% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Achilles Therapeutics PLC is 'Strong Buy'. The recommendation algorithm takes into account all of Achilles Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Achilles Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Achilles and provide practical buy, sell, or hold advice based on investors' constraints. Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Achilles |
Execute Achilles Therapeutics Buy or Sell Advice
The Achilles recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Achilles Therapeutics PLC. Macroaxis does not own or have any residual interests in Achilles Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Achilles Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Achilles Therapeutics Trading Alerts and Improvement Suggestions
| Achilles Therapeutics has some characteristics of a very speculative penny stock | |
| Achilles Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Achilles Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market |
Achilles Therapeutics Returns Distribution Density
The distribution of Achilles Therapeutics' historical returns is an attempt to chart the uncertainty of Achilles Therapeutics' future price movements. The chart of the probability distribution of Achilles Therapeutics daily returns describes the distribution of returns around its average expected value. We use Achilles Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Achilles Therapeutics returns is essential to provide solid investment advice for Achilles Therapeutics.
| Mean Return | 0.63 | Value At Risk | -2.88 | Potential Upside | 3.06 | Standard Deviation | 4.54 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Achilles Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Achilles Stock Institutional Investors
| Shares | Virtu Financial Llc | 2024-06-30 | 22.8 K | Geode Capital Management, Llc | 2024-09-30 | 21.6 K | Two Sigma Investments Llc | 2024-09-30 | 21.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 17.9 K | Baader Bank Inc | 2024-09-30 | 14.2 K | Hrt Financial Llc | 2024-06-30 | 10.9 K | Brave Asset Management Inc | 2024-09-30 | 10 K | Rhumbline Advisers | 2024-06-30 | 4.5 K | Arcadia Investment Management Corp | 2024-09-30 | 3 K | Syncona Portfolio Ltd. | 2024-09-30 | 11.1 M | Bml Capital Management Llc | 2024-09-30 | 4.1 M |
Achilles Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 86.9M | 80.3M | 88.5M | (93.0M) | (41.8M) | (39.7M) | |
| Depreciation | 302K | 772K | 3.3M | 3.7M | 4.7M | 2.4M | |
| Capital Expenditures | 942K | 11.8M | 7.6M | 7.5M | 1.1M | 1.0M | |
| Net Income | (14.0M) | (33.2M) | (61.1M) | (71.2M) | (69.9M) | (66.4M) | |
| End Period Cash Flow | 97.6M | 177.8M | 266.4M | 173.4M | 131.6M | 157.2M | |
| Change To Netincome | 724K | 4.2M | 6.5M | 13.9M | 16.0M | 16.8M |
Achilles Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Achilles Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Achilles Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Achilles stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.46 | |
β | Beta against Dow Jones | 1.38 | |
σ | Overall volatility | 4.61 | |
Ir | Information ratio | 0.11 |
Achilles Therapeutics Volatility Alert
Achilles Therapeutics PLC currently demonstrates below-average downside deviation. It has Information Ratio of 0.11 and Jensen Alpha of 0.46. Achilles Therapeutics PLC is a potential penny stock. Although Achilles Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Achilles Therapeutics PLC. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Achilles instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Achilles Therapeutics Fundamentals Vs Peers
Comparing Achilles Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Achilles Therapeutics' direct or indirect competition across all of the common fundamentals between Achilles Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Achilles Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Achilles Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Achilles Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Achilles Therapeutics to competition |
| Fundamentals | Achilles Therapeutics | Peer Average |
| Return On Equity | -0.44 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Current Valuation | (37.17 M) | 16.62 B |
| Shares Outstanding | 41.09 M | 571.82 M |
| Shares Owned By Insiders | 6.51 % | 10.09 % |
| Shares Owned By Institutions | 59.29 % | 39.21 % |
| Number Of Shares Shorted | 159.25 K | 4.71 M |
| Price To Earning | 0.49 X | 28.72 X |
| Price To Book | 0.42 X | 9.51 X |
| EBITDA | (70.44 M) | 3.9 B |
| Net Income | (69.94 M) | 570.98 M |
| Cash And Equivalents | 201.6 M | 2.7 B |
| Cash Per Share | 4.94 X | 5.01 X |
| Total Debt | 4.62 M | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 11.45 X | 2.16 X |
| Book Value Per Share | 3.46 X | 1.93 K |
| Cash Flow From Operations | (48.45 M) | 971.22 M |
| Short Ratio | 1.69 X | 4.00 X |
| Earnings Per Share | (1.66) X | 3.12 X |
| Price To Earnings To Growth | (0.31) X | 4.89 X |
| Target Price | 4.0 | |
| Number Of Employees | 204 | 18.84 K |
| Beta | 1.34 | -0.15 |
| Market Capitalization | 45.28 M | 19.03 B |
| Total Asset | 161.46 M | 29.47 B |
| Retained Earnings | (259.95 M) | 9.33 B |
| Working Capital | 128.64 M | 1.48 B |
| Net Asset | 161.46 M |
Achilles Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Achilles . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Achilles Therapeutics Buy or Sell Advice
When is the right time to buy or sell Achilles Therapeutics PLC? Buying financial instruments such as Achilles Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Achilles Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronic Equipment Thematic Idea Now
Electronic Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Achilles Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Return On Assets (0.27) | Return On Equity (0.44) |
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.